Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MDX-1401 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MDX-1401 | EXPERIMENTAL | MDX-1401 iv at various doses |
| Name | Type | Description |
|---|---|---|
| MDX-1401 | BIOLOGICAL | IV weekly for 4 weeks |
Inclusion Criteria: * Diagnosis of CD30-positive HL by immunohistochemistry or flow cytometry * Must have failed or relapsed following second line chemotherapy or radiation or failed/relapsed following autologous stem cell transplant * Bi-measurable disease * ECOG Performance Status of 0 - 2 * Meet...
MDX-1401 is an investigational monoclonal antibody being studied for the treatment of Hodgkin's Lymphomas. It is being developed by Bristol-Myers Squibb Company (BMY) and is currently in Phase 1 clinical development.
MDX-1401 targets CD30, a protein expressed on the surface of certain cancer cells. It is being studied in patients with CD30-positive refractory or relapsed Hodgkin's Lymphoma.
MDX-1401 is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY on the stock market.
MDX-1401 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study has been completed.
MDX-1401 has been studied in a Phase 1 clinical trial with the identifier NCT00634452. This trial enrolled 22 patients with CD30-positive refractory or relapsed Hodgkin's Lymphoma and has been completed.
MDX-1401 is a distinct investigational monoclonal antibody developed by Bristol-Myers Squibb. No alternative names for this drug have been disclosed.